Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs Incyte Corporation — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.82, while Incyte Corporation trades at $120.95 (market cap $24.54B). The key difference: Incyte Corporation is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | INCY | |
|---|---|---|
52-Week High | $49.91 | $129.93 |
52-Week Low | $47.57 | $81.61 |
Market Cap | — | $24.54B |
Sector | — | Health |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.835 with minimal daily movement (+0.09%), showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts of $0.11-$0.12. Market sentiment reflects ongoing concerns about Treasury yields and inflation data, with institutional activity showing mixed positioning changes among major holders.
The international bond ETF faces headwinds from rising global yields and inflation pressures, though steady dividend income provides support. Key risks include Federal Reserve policy uncertainty and Middle East geopolitical tensions affecting oil prices. Institutional interest remains active with recent position adjustments, suggesting cautious but engaged professional investor sentiment.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
